Abstract | BACKGROUND: METHODS/DESIGN: This is a multicenter, randomized, placebo-controlled and double-blind trial. A total of 120 patients will be enrolled in this study and will be randomized into two groups. Berberine or placebo will be taken orally for 12 weeks. The primary outcome is the whole body insulin action assessed with the hyperinsulinemic-euglycemic clamp. DISCUSSION: TRIAL REGISTRATION: This study is registered at ClinicalTrials.gov, NCT01138930.
|
Authors | Yan Li, Hongli Ma, Yuehui Zhang, Hongying Kuang, Ernest Hung Yu Ng, Lihui Hou, Xiaoke Wu |
Journal | Trials
(Trials)
Vol. 14
Pg. 226
(Jul 18 2013)
ISSN: 1745-6215 [Electronic] England |
PMID | 23866924
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers
- Blood Glucose
- Hypoglycemic Agents
- Insulin
- Berberine
|
Topics |
- Administration, Oral
- Adolescent
- Adult
- Berberine
(administration & dosage, adverse effects, therapeutic use)
- Biomarkers
(blood)
- Blood Glucose
(drug effects, metabolism)
- China
- Clinical Protocols
- Double-Blind Method
- Female
- Glucose Clamp Technique
- Glucose Tolerance Test
- Humans
- Hypoglycemic Agents
(administration & dosage, adverse effects, therapeutic use)
- Insulin
(blood)
- Insulin Resistance
- Polycystic Ovary Syndrome
(blood, diagnosis, drug therapy, physiopathology)
- Predictive Value of Tests
- Research Design
- Treatment Outcome
- Young Adult
|